Skip to main content

06-27-2018 | Metformin | Article

Metformin monotherapy in children and adolescents with type 2 diabetes mellitus in Japan

Journal: Diabetology International

Authors: Nobuo Matsuura, Shin Amemiya, Shigetaka Sugihara, Tatsuhiko Urakami, Nobuyuki Kikuchi, Hiroshi Kato, Yasuhide Yodo, on behalf of the Study Group of the Pediatric Clinical Trial of Metformin in Japan

Publisher: Springer Japan




To evaluate the safety and effectiveness of metformin monotherapy for 52 weeks, including 24 weeks of treatment and a 28-week extension period for evaluation of long-term safety, in 37 Japanese pediatric patients with type 2 diabetes mellitus.

Research design and methods

This study design was an open-label, non-randomized, multicenter trial. The primary effectiveness endpoint was the changes from baseline to the final visit at 24 weeks in HbA1c. The secondary endpoints were the rate for achieving the treatment goal, and the changes in glycated albumin, fasting blood glucose, fasting insulin, HOMA-IR, and fasting serum lipids. Metformin was administrated at the dose of 500 mg/day up to a maximum of 2000 mg/day taken in two or three divided doses.


The mean change of HbA1c at the final visit at 24 weeks for 20 metformin-naïve patients (Group A) was − 0.66 ± 0.95% and that of 17 already-on metformin patients (Group B) was − 0.98 ± 1.62%. These figures proved the effectiveness of metformin as defined before the study. Secondary effectiveness endpoints were also improved. The improvement of blood glucose, fasting insulin and serum lipid levels proved the effectiveness of metformin without increasing body weight. Adverse effects such as nausea and diarrhea were observed in 35 of the 37 subjects and drug-related adverse events were observed in 19 patients. However, these events were not serious and did not increase with long-term treatment.


Metformin is safe and effective for Japanese pediatric patients with T2DM.
Urakami T, Harada K, Kubota S, Owada M, Nitadori Y, Kitagawa T. Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care. 2005;28:1876–81. CrossRefPubMed
Reinehr T. Type 2 diabetes mellitus in children and adolescents. World J Diabetes. 2013;15:270–81. CrossRef
Today Study Group, Zeitler P, Hirst K, Pyle L, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366:2247–56. CrossRefPubMedCentral
Yokoyama H, Okudaira M, Otani T, Sato A, Miura J, Takaike H, Yamada H, Muto K, Uchigata Y, Ohashi, Iwamoto Y. Higher incidence of diabetic nephropathy in type 2 than type 1 diabetes in early-onset diabetes in Japan. Kidney Int. 2000;58:302–11. CrossRefPubMed
Bjorstad P, Cherney DZ, Maahs DM, Nadeau KJ. Diabetic kidney disease in adolescents with type 2 diabetes: new insights and potential therapies. Curr Diabetes Rep. 2016;16:11. CrossRef
Levers-Landis CE, Walders-Abramson N, Amodei N, Drews KL, Kaplan J, Levitt LE, Lavietes S, Salestsky R, Seldman D, Yasuda P. Longitudinal correlates of health risk behaviors in children and adolescents with type 2 diabetes. J Pediatr. 2015;166:1258–64. CrossRef
Copeland MC, Silverstein J, Moore KR, Prazar GE, Raymer T, Shiffman RN, Springer SC, Thaker VV, Anderson M, Spann SJ, Flinn SK. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics. 2013;131:364–82. CrossRefPubMed
Rosenbloom AL, Silverstein JH, Amemiya S, et al. Type 2 diabetes mellitus in childhood and adolescents. ISPAD Clinical Practice Consensus Guidelines 2009 Compendium. Pediatr Diabetes. 2009;10(suppl. 12):17–32. CrossRefPubMed
Zeitler P, Fu J, Tandon N, et al. Type 2 diabetes mellitus in childhood and adolescents. ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Pediatr Diabetes. 2014;15(suppl. 20):26–46. CrossRefPubMed
Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effects of metformin in pediatric patients with type 2 diabetes. Diabetes Care. 2002;25:89–94. CrossRefPubMed
Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes. Diabetes Care. 2007;30:790–4. CrossRefPubMed
van der Aa MP, van de Garte E, van Mil E, Knibbe C, van der Vorst M. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. Nutr Diabetes. 2016;6:1–10.
Matsuura N, Takeuchi M, Amemiya S, Sugihara S, Yokota Y, Tanaka T, Nakamura H, Sasaki N, Ooki Y, Urakami T, Miyamoto S, Kikuchi N, Kobayashi K, Horikawa R, Kikuchi T. Clinical trial of metformin in children and adolescents with type 2 diabetes mellitus in Japan. J Jpn Diabetes Soc. 2008;51:427–34 (Japanese).
Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type 2 diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;102:491–7. CrossRef
Hazel-Femandez L, Xu Y, Moretz C, Meah Y, Baltz J, Jian J, Kimball E, Bouchard J. Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapy. Curr Med Res Opin. 2015;31:1703–16. CrossRef
Odawara M, Kawamori R, Tajima N, Iwamoto Y, Kageyama S, Yodo Y, Ueki F, Hotta N. Long-term treatment study of global standard dose of metformin in Japanese patients with type 2 diabetes mellitus. Diabetol Int. 2017;8:286–95. CrossRefPubMedPubMedCentral
Narashimhan S, Weinstock R. Youth-onset of type 2 diabetes mellitus: lessons learned from the TODAY Study. Mayo Clin Proc. 2014;89:806–16. CrossRef
Kelsey MM, Geffner ME, Guandalini C, Pyle L, Tamborlane WV, Zeitler P, White Study Group. Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study. Pediatr Diabetes. 2016;17:212–21. CrossRefPubMed

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

GLP-1 receptor agonists

Browse the latest news, clinical trial updates, and expert commentary.